11.08

2.45% 0.26

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $11.08, with a volume of 1.04M. It is up +2.45% in the last 24 hours and up +6.69% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$10.82

Open:

$10.76

24h Volume:

1.04M

Relative Volume:

0.63

Market Cap:

$3.48B

Revenue:

$2.68B

Net Income/Loss:

$-184.45M

P/E Ratio:

-16.28

EPS:

-0.6805

Net Cash Flow:

$229.23M

1W Performance:

+8.15%

1M Performance:

+6.69%

6M Performance:

+39.08%

1Y Performance:

+30.57%

1-Day Range:

$10.68

$11.13

1-Week Range:

$9.99

$11.13

52-Week Range:

$6.685

$11.13

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1139)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2025-05-02

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	11.09	3.40B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	144.48	63.86B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.41	42.46B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.38	41.28B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.48	23.49B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	436.73	19.18B	3.08B	1.24B	1.07B	25.61

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-06-25	Initiated	Goldman	Buy
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

05:52 AM

Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones indexJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com

05:52 AM

05:39 AM

Is Amneal Pharmaceuticals Inc. stock ready for a breakoutAnalyst Upgrade & Community Verified Watchlist Alerts - newser.com

05:39 AM

05:30 AM

Will Amneal Pharmaceuticals Inc. stock benefit from automationJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com

05:30 AM

04:43 AM

Real time breakdown of Amneal Pharmaceuticals Inc. stock performanceWeekly Gains Summary & Safe Capital Allocation Plans - newser.com

04:43 AM

03:22 AM

What analyst consensus says on Amneal Pharmaceuticals Inc. stockWeekly Trend Summary & Community Consensus Stock Picks - newser.com

03:22 AM

01:29 AM

Is Amneal Pharmaceuticals Inc. stock resilient to inflationPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - newser.com

01:29 AM

Nov 02, 2025

How high can Amneal Pharmaceuticals Inc. stock goWeekly Investment Report & Verified Swing Trading Watchlist - newser.com

Nov 02, 2025

Is Amneal Pharmaceuticals Inc. stock a top momentum play2025 Trading Volume Trends & Real-Time Market Trend Scan - newser.com

Nov 02, 2025

Does Amneal Pharmaceuticals Inc. show high probability of rebound2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com

Nov 02, 2025

Candlestick signals on Amneal Pharmaceuticals Inc. stock todayJuly 2025 Outlook & AI Based Buy/Sell Signal Reports - newser.com

Nov 02, 2025

Amneal Pharmaceuticals Reports Strong Q3 2025 Results - MSN

Nov 02, 2025

Amneal Pharmaceuticals Hits New 52-Week High of $10.70 - Markets Mojo

Nov 02, 2025

Nov 01, 2025

Piper Sandler Reaffirms Overweight Rating for Amneal Pharmaceuticals (NASDAQ:AMRX) - MarketBeat

Nov 01, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Option Care Health (OPCH) and Amneal Pharmaceuticals (AMRX) - The Globe and Mail

Nov 01, 2025

Amneal raises 2025 EPS guidance and outlines $300M–$500M CREXONT sales target as portfolio expansion accelerates - MSN

Nov 01, 2025

Amneal Pharmaceuticals stock hits 52-week high at $10.72 By Investing.com - Investing.com Australia

Nov 01, 2025

Oct 31, 2025

Amneal Pharmaceuticals (AMRX): One-Off $55.9M Loss Tests Bull Case Built on High Earnings Growth Forecasts - Sahm

Oct 31, 2025